Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
已完成
1
50.0%
Unknown
1
50.0%
暂无批准数据
- Trinity Biotech secured approximately $7.0 million in additional investment from funds managed by Perceptive Advisors, its largest financial investor and primary lender. - The funding comprises roughly $2.5 million of new debt and $4.5 million of capitalised interest under an amendment to existing financing arrangements. - Trinity Biotech regained compliance with Nasdaq's minimum bid price requirement, with its ADS closing at $1.00 or greater for 10 consecutive business days. - The capital supports strategic initiatives including the CGM+ continuous glucose monitoring platform, the Trinovium subsidiary, and the company's broader business transformation.
- Trinity Biotech and Latch Medical announced a strategic collaboration to integrate CGM+ wearable biosensor data with the Pharma Latch™ intradermal drug delivery platform for metabolic conditions. - The partnership aims to develop precision therapeutic solutions for diabetes, obesity, and other metabolic diseases by using real-time biosensor data to guide drug delivery. - Trinity Biotech has agreed in principle to make a strategic equity investment in Latch Medical, supported by its largest financial investor, Perceptive Advisors. - The collaboration builds on Trinity Biotech's recently announced positive CGM+ clinical trial data and supports its strategy of building an integrated metabolic health platform combining sensing, AI, and therapeutic delivery.
- Trinity Biotech announced successful clinical results for its enhanced EpiCapture prostate cancer test, which achieved 85% clinical accuracy (AUC) in a study of 750 patient samples. - The next-generation urine liquid biopsy test incorporates machine learning algorithms that integrate patient ethnicity with DNA biomarkers to provide more accurate, individualized risk prediction scores. - The company plans to commercialize EpiCapture as a Laboratory Developed Test through its New York State Department of Health certified diagnostics reference laboratory, marking its strategic entry into precision oncology diagnostics. - The enhanced test addresses significant barriers in current prostate cancer diagnostics by offering a less invasive alternative to costly MRI scans and needle biopsies that carry infection risks.
- Trinity Biotech has entered into a collaboration with the University at Buffalo to commercialize proprietary biomarkers for earlier and more accurate detection of Sjögren's Syndrome, addressing a significant diagnostic gap in autoimmune disease management. - The partnership targets Sjögren's Syndrome, which affects up to 4 million Americans and is three times more common than lupus and multiple sclerosis, yet remains widely underdiagnosed with women comprising approximately 90% of cases. - The biomarkers are specifically designed to improve diagnostic performance in early-stage or seronegative patients, utilizing Trinity Biotech's NYSDOH-approved reference laboratory as the launch platform for these innovative assays. - This collaboration represents a strategic milestone in Trinity Biotech's expansion toward high-value specialty diagnostic tests and reinforces the company's focus on autoimmune and immunology-focused diagnostic innovations.
- Trinity Biotech announced agreements with Perceptive Advisors providing $5 million in new funding and extending credit maturity to early 2027 to support growth initiatives. - The company secured up to $60 million in elective debt-to-equity conversion capacity and equity settlement mechanisms for milestone payments related to its continuous glucose monitoring solution. - These arrangements strengthen Trinity Biotech's financial position to advance its CGM+ technology and other diagnostic pipeline projects while reducing overall debt levels.
- Trinity Biotech announced a strategic collaboration with a bioinformatics company to conduct advanced analysis on clinical trial data for EpiCapture, its PCR-based epigenetic liquid biopsy test for prostate cancer monitoring. - The EpiCapture test detects DNA methylation patterns associated with high-grade prostate cancer and offers a non-invasive method to monitor disease progression, potentially reducing unnecessary invasive procedures. - A study published in The Journal of Clinical Oncology – Precision Oncology demonstrated that EpiCapture correctly predicted all high-grade cancers when used alongside the PSA test. - The collaboration supports advancement of the late-stage EpiCapture test toward regulatory approval and commercialization, addressing a significant clinical need in prostate cancer management.
- Trinity Biotech achieved a breakthrough in continuous glucose monitoring by demonstrating its CGM+ system can operate for 15 days without requiring fingerstick calibration. - The company's pre-pivotal trial results show the device delivers accurate glucose readings while employing fewer disposable components at a lower cost point than existing systems. - Trinity Biotech is targeting the $13 billion global CGM market, which is projected to grow to $28 billion by 2030, with a commercial launch planned for mid-2026. - The CGM+ system features a modular design that integrates glucose monitoring with cardiovascular, temperature, and activity tracking in a single wearable device.
- Trinity Biotech announced the launch of an FDA-cleared PreClara Ratio biomarker test for preeclampsia risk assessment, planned for Q3 2025 rollout through its New York reference laboratory. - The sFlt-1/PlGF test targets approximately 500,000 women annually affected by hypertensive disorders of pregnancy in the United States, a leading cause of maternal and neonatal complications. - Recent U.S.-based studies published in March 2025 demonstrated potential neonatal cost savings exceeding $10 million per 1,000 patients when incorporated into standard care. - The service launch establishes groundwork for Trinity Biotech's proprietary PrePsia technology and represents a strategic milestone in the company's maternal health portfolio expansion.
- Trinity Biotech received World Health Organization approval for offshored and outsourced upstream manufacturing of its TrinScreen HIV rapid test, marking a critical milestone in the company's transformation plan. - The regulatory approval enables transition from legacy in-house operations to a more cost-effective and scalable outsourced model while maintaining product integrity and regulatory compliance. - The strategic move is expected to deliver substantial improvements in gross margin and working capital while enhancing supply chain resilience and scalability. - Trinity Biotech plans to implement this new TrinScreen HIV manufacturing model in Q3 2025 as part of broader efforts to streamline operations and reduce fixed costs.
• Trinity Biotech's next-generation CGM system shows significant first-day accuracy improvements, with a 35% MARD improvement and a 50% MAD improvement. • The pre-pivotal trial included 30 participants with Type 1 diabetes, demonstrating superior signal quality and enhanced reliability post-insertion. • Trinity Biotech's CGM system is designed for affordability and sustainability, featuring reusable components and a user-friendly design. • Regulatory submissions in Europe are expected in 2025, followed by a U.S. FDA filing in 2026, targeting both diabetes patients and health-conscious consumers.
